PARP1 and breast carcinoma: Cancer cells with homologous recombination defects, such as ovarian and breast cancer cells with breast cancer susceptibility genes (BRCA) 1/2 mutations, can be induced to differentiate by poly ADP-ribose polymerase (PARP) inhibitors [2].